newsfilter
← Latest News
Business Wire·

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA®